Table 2.

Renal outcomes in SGLT-2 inhibitor cardiovascular outcome trials

Trial	Composite renal outcome measure	Progression of albuminuria	eGFR/creatinine	Incidence of ESRD	Death from a renal cause
EMPA-REG OUTCOME (empagliflozin) n = 7020	Empagliflozin: 12.7% Placebo: 18.8% (HR 0.61)	Empagliflozin: 11.2% Placebo: 16.2% (HR 0.62)	Empagliflozin: 1.5% Placebo: 2.6% (HR 0.56)	Empagliflozin: 0.3% Placebo: 0.6% (HR 0.45)	Empagliflozin: 0.1% Placebo: 0.0%
CANVAS Program (canagliflozin) n = 10,142	Canagliflozin: 5.5a Placebo: 9.0a (HR 0.60)	New macroalbuminuria: Canagliflozin: 15.1a Placebo: 27.6a (HR 0.58)	Canagliflozin: 5.3a Placebo: 8.7a (HR 0.60)	Canagliflozin: 0.4a Placebo: 0.6a (HR 0.77)	Canagliflozin: 0.0a Placebo: 0.2a
CREDENCE trial (canagliflozin) n = 4402	Canagliflozin: 11.1% Placebo: 15.5% (HR 0.70)	Mean urinary ACR 31% less versus placebo	Canagliflozin: 5.4% Placebo: 8.6% (HR 0.60)	Canagliflozin: 5.3% Placebo: 7.5% (HR 0.68)	Canagliflozin: 0.1% Placebo: 0.2%
DECLARE-TIMI 58 (dapagliflozin) n = 17,600	Dapagliflozin: 1.5% Placebo: 2.8% (HR 0.53)	Mean urinary ACR 29% less versus placebo	Dapagliflozin: 1.4% Placebo: 2.6% (HR 0.54)	Dapagliflozin: 0.1% Placebo: 0.2% (HR 0.31)	Dapagliflozin: 0.1% Placebo: 0.1% (HR 0.60)
DAPA-HF (dapagliflozin) n = 4744	Dapagliflozin: 1.2% Placebo: 1.6% (HR 0.71)	Not reported	Not reported	Not reported	Not reported

The number of participants in each trial is denoted by n

eGFR estimated glomerular filtration rate, ESRD end-stage renal disease, HR hazard ratio, ACR albumin-to-creatinine ratio

^aResults presented as the number of participants with an event per 1000 patient years